ArticleMolecular biology and evolution2025
A Trade-Off between Body Mass and Cancer Resistance in Cetaceans Is Mediated by Cell Cycle-Related Gene Evolution.
Article in Molecular biology and evolution, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic Insights into Wildlife Cancer and Conservation Strategies Under the One Health Framework.Veterinary sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cetaceans, well-known for their exceptionally long lifespans and substantial body masses, demonstrate a lower risk of cancer mortality compared to other mammals, consistent with Peto's paradox. Yet, the underlying mechanisms of cancer resistance, possibly evolved due to large body size, remain largely unclear. Here, we conducted an evolutionary analysis of 50 cell cycle-related genes, which play crucial role in both cancer progression and organismal body mass modulation, to investigate the mechanisms underlying the trade-off between body size and cancer resistance in cetaceans. We found that 66.7% (4/6) rapidly evolving genes (i.e. CDK2, CDT1, ORC3, and DBF4) and 50% (2/4) positively selected genes (ORC2 and ORC3) identified in cetaceans are involved in regulating cell cycle checkpoints, which halt the cell cycle in response to damage to allow repair and prevent cancer induction. Additionally, we identified four-body mass-associated genes (CCNE1, ORC5, E2F3, and DBF4) known to regulate cell growth; mutations or dysregulation of these genes can drive uncontrolled proliferation and cancer development. Interestingly, convergent evolution was observed in the African elephant and the bowhead whale at the tumor suppressor gene MYT1, potentially revealing a convergent mechanism of cancer resistance in large-bodied species. Notably, in vitro assays revealed that a cetacean-specific mutation M155T in the rapidly evolving gene CCND1 more effectively suppressed tumor cell proliferation and migration. Overall, our study has provided new insights into how the evolution of cell cycle-related genes balances body mass and cancer resistance in cetaceans, offering molecular support for Peto's paradox.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.